MedTrace Logo

Safety and Efficacy Study of IV Artesunate to Treat Malaria

NCT00298610 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2019-10-01

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine how GMP IV Artesunate is metabolized and cleared by individuals with uncomplicated malaria infection and to determine how fast it eliminates malaria infection from the body.

Conditions

Interventions

DRUG

Artesunate

Intravenous Artesunate (2.4 mg/kg) once a day for three days

DRUG

Malarone

(proguanil/atovaquone) follow-on therapy (4 tablets once daily for three days)

Sponsors & Collaborators

  • Military Infectious Diseases Research Program (MIDRP)

    collaborator NETWORK

  • U.S. Army Medical Research and Development Command

    lead FED

Principal Investigators

  • Shon A Remich, MD · Walter Reed Army Institute of Research (WRAIR)

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-03-31
Primary Completion
2007-10-31
Completion
2007-10-31

Countries

  • Kenya

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00298610 on ClinicalTrials.gov